Organization · Venture Studio
Lucid Bioventures
Lucid Bioventures is a Nordic life science venture builder focused on early-stage drug development projects emerging from academic research. It aims to bridge the gap between academia, venture capital, and pharmaceutical companies.
Overview
What Lucid Bioventures does
What Lucid Bioventures is
Lucid Bioventures is a Nordic life science venture builder focused on early-stage drug development projects emerging from academic research. It aims to bridge the gap between academia, venture capital, and pharmaceutical companies.
How it participates in the startup ecosystem
The current public profile supports funder and program host capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Studio
- Structured capabilities
- Funder · Program host
- Last reviewed
- April 28, 2026
What Venture studio means
A venture studio is an organization that systematically creates new startups by generating or sourcing ideas, validating them, building early products, recruiting founders or operators, providing shared resources, and retaining meaningful equity in the companies it helps create.
Open the glossary entryOfficial channels
Find Lucid Bioventures elsewhere
Open the official website or a supported primary organization account.
Capability profile
Lucid Bioventures as a funder
Investment thesis
Lucid Bioventures aims to reduce biotech company-formation risk by combining scientific diligence, commercial strategy, founding-team creation, seed/follow-on funding, IP support, and network access.
Focus narrative
Lucid Bioventures invests in early-stage therapeutic opportunities characterized by validated science, protectable intellectual property, clear development logic, identifiable pharmaceutical buyer interest, and potential for licensing or acquisition around Phase I. The organization employs a structured, capital-efficient model aimed at reducing early risks and defining exit pathways for investors.
Value beyond capital
Lucid Bioventures provides commercialization support, capital, IP strategy, business development, and access to investor and industry networks for biotechnology breakthroughs from researchers, scientists, and innovators.
Portfolio and track record
- Recorded portfolio count
- 2
Portfolio context
Notable portfolio companies include: GCK3 Therapeutics: Developing antisense oligonucleotide (ASO) therapies targeting GCK-III subfamily kinases for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and hepatocellular carcinoma (HCC). Nebulax Therapeutics: Pioneering ASO therapies aimed at addressing cognitive impairment in schizophrenia, with the goal of restoring cognition and improving patient outcomes.
Capability profile
Lucid Bioventures as a program host
Program thesis
Lucid Bioventures aims to bridge the gap between academia, venture capital, and pharmaceutical companies by focusing on early-stage drug development projects that emerge from validated scientific research.
Focus narrative
Lucid Bioventures invests in early-stage therapeutic opportunities characterized by validated science, protectable intellectual property, clear development logic, identifiable pharmaceutical buyer interest, and potential for licensing or acquisition around Phase I. The organization employs a structured, capital-efficient model aimed at reducing early risks and defining exit pathways for investors.
Value and support
Lucid Bioventures offers a comprehensive venture building model that includes scouting technologies, forming founding teams, developing business strategies, and securing seed and follow-on funding, along with support for scaling companies.
Availability
- Application state
- Not published
Focus and fit
- Stages
- Pre-seed · Seed
Alumni and track record
Alumni context
Notable portfolio companies include GCK3 Therapeutics, which is developing antisense oligonucleotide therapies for metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma, and Nebulax Therapeutics, which is pioneering ASO therapies for cognitive impairment in schizophrenia.
Common questions
What to know about Lucid Bioventures
Upseed classifies Lucid Bioventures under the Venture Studio organization type. Its current public profile includes funder and program host capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 28, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.